DexCom, Inc. $DXCM Shares Acquired by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 31.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,516 shares of the medical device company’s stock after buying an additional 11,933 shares during the quarter. UniSuper Management Pty Ltd’s holdings in DexCom were worth $3,332,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after acquiring an additional 169 shares during the period. Inspire Investing LLC increased its stake in shares of DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares in the last quarter. Inspire Advisors LLC raised its position in shares of DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after purchasing an additional 194 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the last quarter. Finally, STF Management LP lifted its stake in DexCom by 5.5% in the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after buying an additional 211 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $86.00 price target (up previously from $84.00) on shares of DexCom in a report on Friday, January 9th. Citigroup reissued a “buy” rating and issued a $77.00 price objective (up previously from $75.00) on shares of DexCom in a report on Thursday, December 11th. Leerink Partners reiterated an “outperform” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Mizuho lifted their price target on shares of DexCom from $75.00 to $78.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.30.

DexCom Stock Performance

Shares of DexCom stock opened at $73.34 on Tuesday. The firm’s 50 day moving average is $66.71 and its two-hundred day moving average is $70.98. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $28.60 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the firm posted $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.